UK-based Redx Pharma said it expects to start first-in-man studies with RXC006 during 2020 as the first pre-clinical data of the drug candidate has suggested that the compound has great potential as a fibrosis treatment.
Aprea Therapeutics, a biopharmaceutical company engaged in the discovery and development of anticancer compounds that reactivate the tumor suppressor protein, p53, has closed a €50m Series C financing round.
WuXi Biologics and ABL Bio have entered into an exclusive development and clinical manufacturing partnership for multiple bispecific antibodies.
AbCellera, a privately held company that engages in partnerships to discover and develop next-generation therapeutic antibodies, has collaborated with clinical stage biopharmaceutical company Autolus Therapeutics on antibody discovery project.
HOOKIPA Pharma has signed a research collaboration and license agreement with DarwinHealth to develop immunotherapies based on the systematic discovery and prioritization of the next generation of immunogenic, tumor-specific cryptic antigens.
Cyxone said that T20K, its investigational drug for the treatment of multiple sclerosis (MS), has succeeded in a preclinical program by yielding positive results in the toxicology studies.
Zymeworks and BeiGene have entered into a collaboration for the clinical development and commercialization of the former’s investigational ZW25 and ZW49 HER2-targeted bispecific antibodies.
Roche Group’s member Genentech has agreed to acquire US-based biotechnology firm, Jecure Therapeutics, for an undisclosed sum.
Cyclica has partnered with Bayer to drives drug discovery through artificial intelligence (AI)-augmented integrated network of cloud-based technologies.
Vineti has entered into a new partnership with Tessa Therapeutics to advance and scale personalized cell therapies for solid tumors in Asia and world-wide.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.